E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Adult subjects of any ethnicity and either gender with Cutaneous Lupus Erythematosus lesions of Subacute Cutaneous Lupus Erythematosus (SCLE), Discoid Lupus Erythematosus (DLE), Lupus erythematosus tumidus (LET) or Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions and without major organ involvement to investigate the efficacy of fumaric acid esters in the treatment of Cutaneous Lupus Erythematosus lesions. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10056509 |
E.1.2 | Term | Cutaneous lupus erythematosus |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10056509 |
E.1.2 | Term | Cutaneous lupus erythematosus |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
-To evaluate the therapeutic effect of fumaric acid esters (Fumaderm®) in the treatment of Cutaneous Lupus Erythematosus with respect to proportion of responders based on the Revised Cutaneous Lupus Disease Area and Severity Index (RCLASI) activity score for skin lesions at baseline and after 24 weeks of treatment or at the latest assessment for patients who withdrew prematurely (Last Observation Carried Forward, LOCF). |
|
E.2.2 | Secondary objectives of the trial |
-To evaluate the proportion of responders after 12 weeks of treatment. -To evaluate the treatment effect of fumaric acid esters (Fumaderm®) with respect to change from baseline in the total RCLASI activity score for skin lesions in comparison to week 12 and to the last day of treatment. -Time from start of treatment to first responce (time to response). -To evaluate the proportion of failures of therapy after 12 and 24 weeks of treatment. -To evaluate the Patient Assessment of Global Improvement (PAGI) score as well as subject’s assessment of itching and pain assessed by a Visual Analogue Scale (VAS) at baseline and after 12 and 24 weeks of treatment. -To evaluate the safety and tolerability aspects of fumaric acid esters (Fumaderm®) in patients with CLE for the body as a whole. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients of any gender aged from 18 to 70 years; - A clinical and histological diagnosis of CLE (DLE, SCLE, LET, without major systemic involvement) who failed to response to topical corticosteroids; - Total RCLASI activity score of >6 (at least 3 points in at least 2 locations) on an assessment of erythema, scale/hyperkeratosis, edema/infiltration and subcutaneous nodule/plaque of the lesion (mucous membrane lesions/alopecia excluded); - Women of childbearing potential must agree to use at least one primary method of contraception and, at the same time, a secondary method of contraception from the time of screening, throughout trial treatment, and for at least one month after finishing treatment. - Signed informed consent.
|
|
E.4 | Principal exclusion criteria |
- Patients unable to comply with the requirements of the study; - Only scarred cutaneous target lesions without activity; - Systemic Lupus Erythematosus (SLE) with major systemic organ involvement, e.g. clinical significant renal involvement, requiring systemic medical treatment for the disease; - Active skin disease other than CLE or another progressive or serious disease that interferes with the study outcome; - Symptoms of a clinically significant illness that may influence the outcome of the study in the four weeks before and during the study; - Active severe infection diseases, including chronic or localized; - Known malignancies in the last 5 years, other than effective treated non melanoma skin cancer; - Severe liver- or kidney- disease; - Severe gastrointestinal disease, like gastric or duodenal ulcer; - Severe hematologic disorders; - Patients with leucopenia (<3.000/mm3); - Patients with lymphopenia (<500/mm3); - Patients with known hypersensitivity to fumaric acid esters or their derivatives, or to any study medication components; - Topical corticosteroids within 14 days prior to dosing; - Local treatment with fumaric acid derivates; - Initiation or change in the dose of any current systemic medication for the treatment of CLE/SLE prior to the study (time depending on drug class); - Treatment with immunosuppressive drugs for other reasons, 4 weeks prior and within the study; - Concomitant treatment with drugs with a known photosensitizing potential, e.g. tetracyclines, griseofulvin, thiazides, furosemide, sulfonamides or tolebutamide; - Drugs associated to CLE-induction: terbinafine, hydrochlorothiazide, diltiazem, verapamil, nifedipine, nitrendipine, fluorouracil, penicillamine, infliximab, adalimumab, etanercept, pantoprazole; - Drugs interfering/ interacting with fumaric acid esters; - Drugs with nephrotoxic potential, e.g. retinoids, psoralens, methotrexate, cyclosporine, immunosuppressants, cytostatics; - Participation in another clinical trial including the four week period preceding the study or having received a non-licensed drug within the last 3 months prior to the study; - Pregnancy (according to pregnancy test) or nursing; |
|
E.5 End points |
E.5.1 | Primary end point(s) |
ď€Primary efficacy outcome is the response rate at week 24 or at the latest assessment for patients who withdrew prematurely (Last Observation Carried Forward, LOCF). Response is defined as a reduction of 50% in the total RCLASI activity for skin lesions, compared to the baseline value ("RCLASI 50"). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will be completed after the last subject has completed the Study Completion Visit, any repeat assessments associated with this visit have been documented and followed-up appropriately by the Investigator, and the database is closed. This would assure that there will be enough time for statistical analysis and interpretation of the study results |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |